{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-291443","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2025-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.337842+00:00","generated_at":"2026-05-16T17:40:03.275464+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Inhibikase raises ~$93.6M in public offering, advances IKT-001 to Phase 3 PAH trial","bullets":["Offering of 46.1M shares at $1.45/share and pre-funded warrants for 22.9M shares; net proceeds ~$93.6M.","Underwriters granted 30-day option to purchase up to 10.3M additional shares.","Company amended Series A-1 and B-1 warrants to reflect plan to advance IKT-001 to global pivotal Phase 3 trial in PAH.","Offering expected to close November 24, 2025; shelf registration effective June 27, 2025.","Jefferies, BofA Securities, and Cantor Fitzgerald are representatives of the underwriters."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-291443","json":"https://secwatch.observer/filing/0001193125-25-291443.json","markdown":"https://secwatch.observer/filing/0001193125-25-291443.md","text":"https://secwatch.observer/filing/0001193125-25-291443.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525291443/0001193125-25-291443-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525291443/d65626d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:40:03.275464+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0494ac77869aff49bf43f1027e9bb79f2dc51fbf","claim":"Inhibikase Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, BofA Securities, Inc. and Cantor Fitzgerald & Co., as representatives of the several underwriters (effective 2025-11-20).","evidence_excerpt":"On November 20, 2025, Inhibikase Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, BofA Securities, Inc. and Cantor Fitzgerald & Co., as representatives of the several underwriters listed on Schedule A thereto (collectively, the “Underwriters”), relating to an underwritten public offering (the “Offering”) of (i) 46,091,739 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and (ii) in lieu of Common Stock to certain investors, pre-funded warrants to purchase up to an aggregate of 22,873,779 shares of Common Stock (the “Pre-Funded Warrants” and the Common Stock issuable upon exercise of the Pre-Funded Warrants, the “Warrant Shares”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525291443/0001193125-25-291443-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Jefferies LLC, BofA Securities, Inc. and Cantor Fitzgerald & Co., as representatives of the several underwriters"},{"label":"Effective","value":"2025-11-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}